6652 Share Price Performance
NT$6.00
-1.90 (-24.05%)
Price NT$6.00
Share Pricen/a
No recently updated narratives available.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded in 1994 and is headquartered in Taipei, Taiwan.